Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
|Slideshows|May 17, 2018
- Vol. 164 No. 5
- Volume 164
- Issue 5
Five Ways the New Merck Differs from the 1899 Edition
Author(s)Valerie DeBenedette
Now in its 20th edition, the ultimate medical guide looks (and weighs) a lot different than it did over 100 years ago.
Advertisement
Articles in this issue
over 8 years ago
Top Ways Pharmacists’ Roles Are Changingover 8 years ago
Small Doses News for Pharmacists May 2018over 8 years ago
Ramadan, Medications, and the Pharmacistover 8 years ago
Are There Too Many Pharmacists?over 8 years ago
It's Time for Pharmacists to Carve Out a New Roleover 8 years ago
It's Time to Rethink Pharmacy Tech Staffingover 8 years ago
Four Ways to Help Pharmacy Technicians Improve Job Performanceover 8 years ago
Ibalizumab-uiyk (Trogarzo) for Multi-Drug-Resistant HIV-1over 8 years ago
Why I Became a Board-Certified Geriatric Pharmacistover 8 years ago
Drug Makers Find New Ways to Thwart Generic CompetitionAdvertisement
Related to this article
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Advertisement
Advertisement
Trending on Drug Topics
1
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
2
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
3
Pharmacies Face Persistent MFP Cash Crunch Amid PBM, 340B Shifts
4
COVID-19, Flu Shots Coadministered Are Well-Tolerated in Pregnancy
5